Tier-1 MVNO Selects Tecnotree's AI-Native BSS for Multi-Country Transformation Across UK & Europe
ESPOO, Finland--(BUSINESS WIRE)--Tecnotree, the global pioneer in AI-native Digital BSS and fintech platforms, has announced a major multi-year, multi-country agreement with a Tier-1 Mobile Virtual Network Operator (MVNO) to transform its operations across the United Kingdom and Europe. The deal, valued at USD 19.58 million over five years, positions Tecnotree at the forefront of next-generation MVNO enablement in mature, highly competitive telecom markets.
This engagement will see the full-stack replacement of the MVNO's legacy systems with Tecnotree's composable, cloud-native BSS—an AI-first, TM Forum ODA-aligned platform engineered for speed, scale, and interoperability. Designed to unlock real-time personalization, agile service orchestration, and embedded financial ecosystems, this transformation lays the foundation for the MVNO to compete with intelligence and grow with intent.
The deployment will begin in H2 2025, with revenue recognition expected to commence from the same period, and expanding its footprint in high-potential European markets.
George Glass, CTO, TM Forum, said:
'This announcement exemplifies the kind of agile, AI-native transformation that TM Forum's Open Digital Architecture was created to support. By embracing open standards and composable, cloud-native design, Tecnotree is enabling MVNOs to unlock speed, intelligence, and interoperability at scale. This is the blueprint for how digital service providers can future-proof their operations and thrive in a rapidly evolving ecosystem.'
Padma Ravichander, CEO of Tecnotree, said:
'We are not just deploying systems—we are delivering the future. This collaboration represents the new paradigm of telecom transformation: lean, AI-native, ethically governed, and designed for human-centric scale. We see MVNOs not as offshoots, but as bold innovators—and our platform gives them the intelligence infrastructure to lead.'
Prianca Ravichander, CMO & CCO of Tecnotree, added:
'The MVNO market is entering its next S-curve of growth—driven by AI, composability, and consent-based monetization. With Tecnotree's digital core at the center, we're enabling real-time, value-led engagement across services, networks, and financial touchpoints. This isn't a system swap—it's a strategic reset.'
Strategic & Technical Highlights:
AI-Native Digital BSS: Microservices architecture enabling modular, scalable service rollouts with Sensa
CVM & Real-Time Decisioning: ML-driven orchestration and KPI-governed automation with Moments
Composable Intelligence: Unified catalog, agile monetization, and dynamic product creation
Financial Layer Integration: Built-in Diwa wallet to support loyalty, payments, and inclusion
TM Forum ODA Alignment: Open API ecosystem to accelerate ecosystem partnerships
Multi-Country Intelligence Core: Federated platform control with localized adaptability
Tecnotree's expansion into developed MVNO markets is underpinned by an industry-shaping strategy: decoupling infrastructure from innovation, and replacing siloed systems with unified, learning platforms that grow smarter with every interaction.
About Tecnotree
Tecnotree is a 5G-ready digital Business Support System (BSS) player, with AI/ML capabilities and multi-cloud extensibility. Tecnotree leads the way on the TM Forum Open API Conformance with 59 certified Open APIs including 9 real-world open APIs, a testament to the company's commitment to excellence, and continuously striving to deliver differentiated experiences and services to both CSPs and DSPs. Our agile and open-source digital BSS Stack comprises the full range (order-to-cash) of business processes and subscription management for telecom and other digital services industries creating opportunities beyond connectivity. Tecnotree also provides Fintech and B2B2X multi-experience digital marketplace to its subscriber base through the Tecnotree Moments platform to empower digitally connected communities across gaming, health, education, OTT, and other vertical ecosystems. Tecnotree is listed on the Helsinki Nasdaq (TEM1V).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
Canada to hit NATO spending target this year as it shifts defense focus toward EU
Canada will reach NATO's defense spending target of 2% of GDP this year, five years ahead of schedule, Prime Minister Mark Carney announced on June 9. Speaking at the University of Toronto, Carney said the move is part of a strategic pivot away from reliance on the U.S. and toward deeper cooperation with the European Union, citing growing security threats from Russia, China, and other adversaries. Carney said Canada's current military capabilities are inadequate, noting that only one of four submarines is operational and much of the maritime and land fleet is outdated. To reverse this trend, his government is launching a $6.8 (9.3 billion Canadian dollars) boost to the defense budget for 2025-26. The investment will be tabled in Parliament through supplementary estimates and directed toward rebuilding the Canadian Armed Forces, upgrading equipment, and expanding domestic production capabilities. The new defense posture includes reassessing major procurement decisions, such as the planned purchase of U.S.-made F-35 jets, and prioritizing partnerships with European firms for equipment acquisitions. Carney emphasized that three-quarters of Canada's defense capital spending has gone to the U.S., a pattern he said must end. "We're doing this for us," Carney was quoted as saying. "Relatedly we're doing it as a strong NATO partner, we're a firm believer in NATO, and we're standing shoulder to shoulder with our NATO allies, we'll continue to do so. ." Carney's announcement comes just ahead of the NATO leaders' summit in late June, where member states are expected to commit to higher defense spending thresholds of up to 5%. The prime minister said Canada would support a new NATO defense industrial pledge and participate in the EU's ReArm Europe initiative. He added that future cooperation with the EU will be a major theme of the upcoming Canada-EU summit. Read also: Ukraine war latest: Ukraine shoots down nearly 500 drones, missiles in Russian record strike, Air Force says We've been working hard to bring you independent, locally-sourced news from Ukraine. Consider supporting the Kyiv Independent.
Yahoo
an hour ago
- Yahoo
Five things to know about Canada's plan to meet the NATO defence spending target
OTTAWA — Prime Minister Mark Carney is promising that Canada will quickly boost its defence spending to hit the NATO member target of two per cent of national GDP this year. Canada has long promised to meet the target but has never had a detailed plan to get there. The announcement comes as NATO allies prepare for talks on raising the spending target to five per cent at the annual summit this month. Here's what you need to know about the announcement. 1. What is the NATO spending target? All NATO allies, Canada included, committed to spending the equivalent of two per cent of their GDP on defence in 2006. In 2014, NATO leaders agreed formally that countries that were not meeting the target must move toward it within a decade. After Russia launched its full-scale invasion of Ukraine in 2022, allies agreed at the 2023 NATO summit to make two per cent the minimum spending target. Many European countries have rapidly scaled up their defence spending in response to Russia's war on Ukraine. As of this year, 22 of the 32 NATO member states are spending at least two per cent of their national GDP on defence. Canada is not among them. A leaked Pentagon document obtained by The Washington Post in 2023 quoted then-prime minister Justin Trudeau telling NATO officials that Canada would not meet the two per cent target. Under pressure from allies, the Trudeau government later promised to hit the two per cent benchmark by 2032. In January, then-defence minister Bill Blair told reporters he was trying to speed up that timeline to 2027. 2. Why is the target changing? At this year's NATO leaders' summit in The Hague, allies will discuss a proposal to boost the spending target to five per cent of GDP. That's expected to be broken down into two parts — 3.5 per cent for what NATO calls core defence spending and another 1.5 per cent for a broader category of defence and security-related spending. NATO Secretary-General Mark Rutte told reporters last week there was "broad support" among allies for the change and that he had total confidence they would agree to it at the summit, which is being held June 24-26. The change is seen as a response to U.S. President Donald Trump's demands for allies to pull more weight in NATO. Among NATO members, the U.S. spends the most on its military in dollar terms. In March, Trump suggested America might not defend its allies if they don't meet the target. "If they don't pay, I'm not going to defend them," he said. According to NATO's most recent figures, U.S. defence spending was estimated at 3.19 per cent of GDP in 2024, down from 3.68 per cent a decade ago. It's the only NATO ally whose defence spending has dropped since 2014. 3. How much is Canada spending on defence? According to the latest NATO projections, Canada was on track to spend 1.45 per cent of GDP on defence in 2024-25. NATO allies also have agreed that 20 per cent of their spending should go toward equipment. In 2024, Canada was on track to spend 17.8 per cent of its total on equipment, making it one of only three countries to miss both parts of the target. Carney's announcement on Monday amounts to another $9.3 billion in spending in this fiscal year, 2025-26. Senior government officials told reporters at a briefing Monday morning that the country's defence spending for the fiscal year was projected to be $53.4 billion. With the announcement of this new spending, that sum is expected to rise to $62.7 billion for 2025-26 — or two per cent of Canada's national GDP, which is estimated at just over $3.1 trillion this year. While most of that — $53.4 billion — is Department of National Defence spending, about $14 billion is going to other government departments, including $370 million for the Communications Security Establishment. 3. What is the money being spent on? A large amount of the spending announced on Monday — $2.63 billion — is meant to "empower the military to recruit and retain the personnel needed to carry out its mandate," said a Government of Canada press release. The government says that funding will help accelerate military recruitment and expand the civilian defence workforce. It includes a pay raise for members. The Canadian Armed Forces is short more than 13,000 personnel in its regular and reserve forces. In February, Chief of the Defence Staff Gen. Jennie Carignan said the Armed Forces was on track to meet its recruitment goal of enrolling 6,496 members this fiscal year. The military said it was aiming to reach its approved strength of 71,500 regular forces members and 30,000 reserve members by April 2029. Another $2.1 billion is set aside to diversify Canada's defence partnerships and help build the domestic defence industry. Carney has said Canada wants to join ReArm Europe, an 800 billion-euro plan to beef up the defence of EU countries. Government officials said Monday that $2.1 billion could help Canada enter joint procurements or multilateral initiatives with other countries. 5. What is happening with the Coast Guard? The government is planning to include $2.5 billion it spends on the Canadian Coast Guard in its NATO spending this year — about 60 per cent of the agency's total budget. The Coast Guard will remain part of the Department of Fisheries and Oceans. It's responsible for ensuring the safety of people in Canadian waters, carrying out search-and-rescue operations and conducting research, and has a fleet of icebreakers. The Coast Guard also has a mandate to "ensure Canada's sovereignty and security by establishing a strong federal presence in our waters," according to the Government of Canada. Government officials said there is no plan to arm the Coast Guard or its members. They say its inclusion in Canada's overall defence and security strategy reflects its role in providing what they call maritime domain awareness. The intent, officials told reporters, is to improve inter-service communication, particularly in the Arctic region. The increased co-operation could involve sending military members on Coast Guard trips, for example. The government said it's boosting the Coast Guard budget by $100 million. — With files from Kyle Duggan and The Associated Press This report by The Canadian Press was first published June 9, 2025. The Canadian Press Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
HER2+ Gastric Cancer (including GEJ) Market to Increase at a Remarkable Growth Rate of 13% During the Study Period (2020-2034)
The overall HER2+ gastric cancer market is projected to grow, driven by increasing biomarker testing, better patient selection, and continued advancements in HER2-targeted ADCs, bispecific antibodies, and novel immune-based approaches. Additionally, the launch of therapies such as Zanidatamab (Jazz Pharmaceuticals), Rilvegostomig (AstraZeneca), Evorpacept (ALX Oncology), and others in the future is expected to bring a positive shift in the treatment landscape of HER2+ gastric cancer. LAS VEGAS, June 9, 2025 /PRNewswire/ -- DelveInsight's HER2+ Gastric Cancer (including GEJ) Market report includes a comprehensive understanding of current treatment practices, emerging HER2+ gastric cancer therapies, market share of individual therapies, and current and forecasted HER2+ gastric cancer market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Key Takeaways from the HER2+ Gastric Cancer Market Report As per DelveInsight's analysis, the total market size of HER2+ gastric cancer (including GEJ) in the 7MM is approximately USD 700 million in 2024 and is projected to increase during the forecast period (2025–2034). In 2024, among the current therapies for HER2+ gastric cancer, the largest revenue was generated by Trastuzumab ± Chemotherapy, i.e., USD 140 million in the United States. The total number of incident cases of HER2+ gastric cancer in the 7MM accounted for approximately. 45,000 in 2024. These cases are expected to increase by 2034. Leading HER2+ gastric cancer companies, such as AstraZeneca/Daiichi Sankyo, Merck, Jazz Pharmaceuticals, BeiGene, Zymeworks, Shanghai Henlius Biotech, AbClon, ALX Oncology, Artiva Biotherapeutics, GC Cell, KLUS Pharma, Shanghai Miracogen, Pfizer, Bayer, Enliven Therapeutics, Ambrx, NovoCodex, Mersana Therapeutics, GSK, SystImmune, and others, are developing novel HER2+ Gastric cancer therapies that can be available in the HER2+ gastric cancer market in the coming years. Daiichi Sankyo and AstraZeneca's ENHERTU (trastuzumab deruxtecan), is the only approved therapy for the treatment of advanced or metastatic HER2+ gastric cancer for 2L therapy. The drug received accelerated approval in January 2021. Along with ENHERTU (trastuzumab deruxtecan), KEYTRUDA (pembrolizumab), and HERCEPTIN (trastuzumab) are approved for HER2+ gastric cancer for 1L therapy. Daiichi Sankyo and AstraZeneca's ENHERTU is also expanding into the first-line treatment setting, which is expected to increase its patient share and, consequently, drive growth in the market size. Some of the key HER2+ gastric cancer emerging therapies in the pipeline include ZIIHERA (zanidatamab), Rilvegostomig, HLX22 (AC101), Evorpacept (ALX148), TUKYSA (tucatinib), BAY2927088, AB-201 (GCC2003, HER2 CAR-NK), A166 (Trastuzumab botidotin), MRG002, AIDIXI (disitamab vedotin), BAY2701439, ELVN-002, ARX788, XMT-2056, BL-M07D1, and others. Data presented during the recent ASCO 2025 meeting showed that ENHERTU extended overall survival for more than 3 months in patients with advanced HER2-positive gastric or GEJA following progression on first-line therapy, based on the Phase III DESTINY-Gastric04 trial. In February 2025, AstraZeneca anticipated a data readout from the Phase Ib/II (NCT04379596, DESTINY-Gastric03) trial, which was focused on treating metastatic or unresectable HER2+ gastric cancer, GEJ, and GEA, in 2026. In February 2025, AstraZeneca expected the first patient dosing of ENHERTU (NCT06731478, DESTINY-Gastric05) for HER2+ first-line locally advanced or metastatic gastric cancer or GEJ adenocarcinoma to begin in Q1 2025, with data anticipated to be available after 2026. In the January 2025 presentation, Jazz Pharmaceuticals anticipated the potential approval and launch of zanidatamab as a first-line treatment for GEA in 2026. Additionally, the company is also looking forward to expanding its market strategy for zanidatamab in 2026. In January 2025, ALX Oncology presented positive updated data from the ASPEN-06 Phase II clinical trial at the 2025 ASCO Gastrointestinal Cancers Symposium, demonstrating that the company's investigational CD47-blocker, evorpacept, produces a durable clinical response and exhibits a well-tolerated safety profile in patients with previously treated HER2+ advanced gastric cancer or GEJ cancer. Discover which therapies are expected to grab the HER2+ gastric cancer market share @ HER2+ Gastric Cancer Market Report HER2+ Gastric Cancer Overview Gastric cancer is the fifth most common type of cancer and the fourth leading cause of cancer-related deaths worldwide. HER2, also known as HER2/neu or ERBB2, is found in approximately 15–30% of gastric cancers, including those at the Gastroesophageal Junction (GEJ). It is located on chromosome 17q21 and is part of the EGFR family, which includes EGFR/HER1, HER3, and HER4. The ligand for the HER2 tyrosine kinase receptor remains unidentified. HER2 can form both homodimers and heterodimers with other EGFR family receptors, and overexpression of HER2 can result in ligand-independent activation. In gastric cancer, ERBB2 mutations are most commonly found in the CIN subtype, primarily consisting of missense mutations (74%), with smaller proportions of insertions (22%) and fusions (0.7%). HER2 expression is more frequently observed in the intestinal subtype (according to Lauren's classification), as well as in proximal gastric cancer, GEJ cancer, metastatic disease (particularly liver metastasis), and lymph node involvement. HER2+ Gastric Cancer Epidemiology Segmentation In the 7MM, in 2024, among all the HER2+ Gastric cancer indications, breast cancer accounted for the highest number of incident cases, while ovarian cancer occupied the bottom of the ladder. The HER2+ gastric cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Incident Cases of Gastric Cancer (including GEJ) Gender-Specific Cases of Gastric Cancer (including GEJ) Stage-Specific Cases of Gastric Cancer (including GEJ) Total Incident Cases of HER2+ Gastric Cancer (including GEJ) Total Incident Cases of Advanced HER2+ Gastric Cancer (including GEJ) HER2+ Gastric Cancer Treatment Market HER2, which is overexpressed or amplified in 6–36% of gastric cancer patients, represents a key target in the development of novel treatment strategies for metastatic gastric cancer. While surgical resection remains the primary treatment and can cure patients with early-stage cancer, the survival rates for those with advanced resectable gastric or gastroesophageal junction cancers remain low, despite the introduction of new treatments like perioperative chemotherapy or adjuvant chemoradiation. For patients diagnosed with early-stage disease, gastrectomy is the standard treatment. However, survival rates for those with advanced resectable cancers are still poor, even with the addition of new therapies such as perioperative chemotherapy or adjuvant chemoradiation. Treatment for HER2-positive gastric cancer depends on factors such as tumor size, location, and the patient's overall health. The humanized monoclonal antibody HERCEPTIN (trastuzumab) targets HER2, inhibiting the growth and survival of HER2-dependent tumors. Alongside HERCEPTIN, KEYTRUDA (Merck), one of the first therapies approved for gastric cancer, works by binding to the Programmed Cell Death-1 (PD-1) receptor, blocking its interaction with PD-L1 and PD-L2, and reversing PD-1 pathway-mediated immune suppression, including the antitumor immune response. Most recent approvals for targeted therapies, such as ENHERTU (Daiichi Sankyo) and AIDIXI (Remegen Biosciences), are used in second- and third-line treatments for gastric cancer. Learn more about the FDA-approved HER2+ gastric cancer therapies @ HER2+ Gastric Cancer Treatment Drugs Key Emerging HER2+ Gastric Cancer and Companies Various new therapies are in development with a focus on the mentioned limitations of the currently approved drugs. Some of the most prominent ones include Evorpacept (ALX Oncology), Zanidatamab (Jazz Pharmaceuticals), IAM1363 (Iambic Therapeutics), ELVN-002 (Enliven Therapeutics), ARX788 (Ambrx), Rilvegostomig (AstraZeneca), and others. These emerging drugs play a vital part in fulfilling the unmet need for the treatment approach of HER2+ gastric cancer. Although the space is quite active and various trials are underway to treat patients with HER2+ gastric cancer, continuous efforts are further needed to develop novel drugs that would be more effective and less toxic. ZIIHERA is a bispecific antibody targeting HER2, binding to two extracellular sites on the HER2 protein. In November 2024, the FDA granted accelerated approval for ZIIHERA for adult patients with previously treated, unresectable, or metastatic HER2+ (immunohistochemistry 3+) biliary tract cancer (BTC), identified through an FDA-approved test. Jazz Pharmaceuticals expects to release top-line data in the second quarter of 2025 from the Phase III HERIZON-GEA-01 trial (NCT05152147), which is assessing zanidatamab combined with chemotherapy, with or without tislelizumab, as a first-line treatment for HER2-positive metastatic gastric and esophageal adenocarcinoma (GEA). According to the presentation, Jazz Pharmaceuticals aims to potentially approve and launch zanidatamab as a first-line treatment for gastric cancer in 2026. The company is also planning to expand its market strategy for zanidatamab in 2026. HLX22 (AC101), a novel anti-HER2 monoclonal antibody developed by AbClon and further advanced by Henlius, is currently under investigation. In November 2024, Henlius Biotech announced that the first patient was dosed in the Phase III international multicenter clinical trial (HLX22-GC-301) for HLX22. In October 2024, Henlius received approval from Japan's PMDA for the Clinical Trial Notification (CTN) of a Phase III international multicenter study of HLX22, in combination with trastuzumab and chemotherapy, as a first-line treatment for HER2-positive advanced gastric cancer. The other therapies in the HER2+ gastric cancer pipeline include TUKYSA (tucatinib): Pfizer BAY2927088: Bayer AB-201 (GCC2003, HER2 CAR-NK): Artiva Biotherapeutics and GC Cell A166 (Trastuzumab botidotin): KLUS Pharma MRG002: Shanghai Miracogen AIDIXI (disitamab vedotin): Pfizer BAY2701439: Bayer XMT-2056: Mersana Therapeutics and GSK BL-M07D1: SystImmune and others The anticipated launch of these emerging therapies are poised to transform the HER2+ gastric cancer market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the HER2+ gastric cancer market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about HER2+ gastric cancer drug clinical trials, visit @ HER2+ Gastric Cancer Drugs HER2+ Gastric Cancer Market Dynamics The HER2+ gastric cancer market dynamics are expected to change in the coming years. HER2-targeted therapies, such as HERCEPTIN, ENHERTU, and anti-PD1 therapy KEYTRUDA, offer more precise treatment by improving efficacy and minimizing side effects compared to traditional chemotherapy. Daiichi Sankyo and AstraZeneca's ENHERTU is expanding into the first-line treatment setting, which is expected to increase its patient share and drive market growth. There is growing research interest in combining next-generation HER2 inhibitors or bispecific antibodies with Immune Checkpoint Inhibitors (ICIs), presenting significant opportunities to enhance treatment efficacy and improve patient survival. Additionally, the HER2+ gastric cancer market is projected to grow due to increased incidence rates, an aging population, and advancements in treatment methodologies, potentially leading to more investment in research and development. Furthermore, potential therapies are being investigated for the treatment of HER2+ gastric cancer, and it is safe to predict that the treatment space will significantly impact the HER2+ gastric cancer market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the HER2+ gastric cancer market in the 7MM. However, several factors may impede the growth of the HER2+ gastric cancer market. HER2+ gastric cancer is an aggressive form of the disease with a significantly high mortality rate, poor survival rates, and a poor prognosis due to factors such as low screening rates, high rates of refractory/relapsed tumors, and the advanced age of patients. The complexity of tumor biology, including intratumoral heterogeneity, poses challenges to effective treatment strategies and limits the efficacy of current therapies. Additionally, HER2+ gastric cancer is prone to developing resistance to targeted therapies, highlighting the need for the continuous development of next-generation agents, which further increases R&D costs. Moreover, HER2+ gastric cancer treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the HER2+ gastric cancer market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the HER2+ gastric cancer market growth. HER2+ Gastric Cancer Report Metrics Details Study Period 2020–2034 HER2+ Gastric Cancer Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] HER2+ Gastric Cancer Market CAGR 13 % HER2+ Gastric Cancer Market Size in 2024 USD 700 Million Key HER2+ Gastric Cancer Companies AstraZeneca/Daiichi SankyoJazz Pharmaceuticals, BeiGene, Zymeworks, Merck, Shanghai Henlius Biotech, AbClon, ALX Oncology, Artiva Biotherapeutics, GC Cell, KLUS Pharma, Shanghai Miracogen, Pfizer, Bayer, Enliven Therapeutics, Ambrx, NovoCodex, Mersana Therapeutics, GSK, SystImmune, and others Key HER2+ Gastric Cancer Therapies ENHERTU, KEYTRUDA, ZIIHERA (zanidatamab), Rilvegostomig, HLX22 (AC101), Evorpacept (ALX148), TUKYSA (tucatinib), BAY2927088, AB-201 (GCC2003, HER2 CAR-NK) A166 (Trastuzumab botidotin), MRG002, AIDIXI (disitamab vedotin), BAY2701439, ELVN-002, ARX788, XMT-2056, BL-M07D1, and others Scope of the HER2+ Gastric Cancer Market Report HER2+ Gastric Cancer Therapeutic Assessment: HER2+ Gastric Cancer current marketed and emerging therapies HER2+ Gastric Cancer Market Dynamics: Conjoint Analysis of Emerging HER2+ Gastric Cancer Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, HER2+ Gastric Cancer Market Access and Reimbursement Discover more about HER2+ gastric cancer drugs in development @ HER2+ Gastric Cancer Clinical Trials Table of Contents 1 Key Insights 2 Report Introduction 3 Executive Summary 4 Epidemiology and Market Methodology 5 HER2+ Gastric Cancer Market Overview at a Glance 5.1 Market Share (%) Distribution of HER2+ Gastric Cancer by Line of Therapies in 2020 in the 7MM 5.2 Market Share (%) Distribution of HER2+ Gastric Cancer by Line of Therapies in 2034 in the 7MM 5.3 Market Share (%) Distribution of HER2+ Gastric Cancer by Therapies in 2020 in the 7MM 5.4 Market Share (%) Distribution of HER2+ Gastric Cancer by Therapies in 2034 in the 7MM 6 Key Events 7 Disease Background and Overview 7.1 Introduction 7.2 Molecular Subtypes of Gastric Cancer 7.3 HER2+ Gastric Cancer 7.4 Causes and Risk Factors Related to Gastric Cancer 7.5 Clinical Manifestations Related to Gastric Cancer 7.6 Diagnosis Related to Gastric Cancer 7.7 Staging of Gastric Cancer 7.8 Current Treatment Practices: Gastric Cancer 7.8.1 Treatment for HER2+ Gastric Cancer 8 Guidelines and Recommendations for HER2+ Gastric Cancer 8.1 PAN-ASIAN ADAPTED (PAGA) ESMO CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS, TREATMENT, AND FOLLOW-UP OF PATIENTS WITH GASTRIC CANCER (2024) 8.2 NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) GUIDELINES FOR GASTRIC CANCER (2024) 8.3 NICE GUIDELINES FOR OESOPHAGO-GASTRIC CANCER (2023) 8.4 GASTRIC CANCER: ESMO CLINICAL PRACTICE GUIDELINE FOR DIAGNOSIS, TREATMENT AND FOLLOW-UP (2022) 8.5 JAPANESE GASTRIC CANCER TREATMENT GUIDELINES (2021) 9 Epidemiology and Patient Population 9.1 Key Findings 9.2 Assumptions and Rationale: 7MM 9.3 Total Incident Cases of Gastric Cancer (including GEJ) in the 7MM 9.4 United States 9.4.1 Total Incident Cases of Gastric Cancer (including GEJ) in the United States 9.4.2 Gender-specific Cases of Gastric Cancer (including GEJ) in the United States 9.4.3 Stage-specific Cases of Gastric Cancer (including GEJ) in the United States 9.4.4 Total Incident Cases of HER2+ Gastric Cancer (including GEJ) in the United States 9.4.5 Total Incident Cases of Advanced HER2+ Gastric Cancer (including GEJ) in the United States 9.5 EU4 and the UK 9.5.1 Total Incident Cases of Gastric Cancer (including GEJ) in EU4 and the UK 9.5.2 Gender-specific Cases of Gastric Cancer (including GEJ) in EU4 and the UK 9.5.3 Stage-specific Cases of Gastric Cancer (including GEJ) in EU4 and the UK 9.5.4 Total Incident Cases of HER2+ Gastric Cancer (including GEJ) in EU4 and the UK 9.5.5 Total Incident Cases of Advanced HER2+ Gastric Cancer in EU4 and the UK 9.6 Japan 9.6.1 Total Incident Cases of Gastric Cancer (including GEJ) in Japan 9.6.2 Gender-specific Cases of Gastric Cancer (including GEJ) in Japan 9.6.3 Stage-specific Cases of Gastric Cancer (including GEJ) in Japan 9.6.4 Total Incident Cases of HER2+ Gastric Cancer (including GEJ) in Japan 9.6.5 Total Incident Cases of Advanced HER2+ Gastric Cancer (including GEJ) in Japan 10 Patient Journey 11 Marketed Drug 11.1 Key Competitors 11.2 KEYTRUDA (pembrolizumab): Merck 11.2.1 Product Description 11.2.2 Regulatory Milestones 11.2.3 Other Development Activities 11.2.4 Clinical Development 11.2.5 Safety and Efficacy 11.3 ENHERTU (trastuzumab deruxtecan): Daiichi Sankyo and AstraZeneca 11.3.1 Product Description 11.3.2 Regulatory Milestones 11.3.3 Other Development Activities 11.3.4 Clinical Development 11.3.5 Safety and Efficacy 12 Emerging Therapies 12.1 Key Cross Competition 12.2 ZIIHERA (zanidatamab): Jazz Pharmaceuticals, BeiGene, and Zymeworks 12.2.1 Product Description 12.2.2 Other Developmental Activities 12.2.3 Clinical Development 12.2.4 Safety and Efficacy 12.3 Rilvegostomig: AstraZeneca 12.3.1 Product Description 12.3.2 Clinical Development 12.4 HLX22 (AC101): Shanghai Henlius Biotech and AbClon 12.4.1 Product Description 12.4.2 Other Development Activity 12.4.3 Clinical Development 12.4.4 Safety and Efficacy 12.5 Evorpacept (ALX148): ALX Oncology 12.5.1 Product Description 12.5.2 Other Developmental Activities 12.5.3 Clinical Development 12.5.4 Safety and Efficacy 12.6 TUKYSA (tucatinib): Pfizer 12.6.1 Product Description 12.6.2 Other Development Activity 12.6.3 Clinical Development 12.6.4 Safety and Efficacy 13 HER2+ Gastric Cancer (including GEJ): 7MM Analysis 13.1 Key Findings 13.2 Market Outlook 13.3 Conjoint Analysis 13.4 Key Market Forecast Assumptions 13.4.1 Cost Assumptions and Rebates 13.4.2 Pricing Trends 13.4.3 Analogue Assessment 13.4.4 Launch Year and Therapy Uptake 13.5 Total Market Size of HER2+ Gastric Cancer (including GEJ) in the 7MM 13.6 United States Market Size 13.6.1 Total Market Size of HER2+ Gastric Cancer (including GEJ) in the United States 13.6.2 Market Size of HER2+ Gastric Cancer (including GEJ) by Current and Emerging Therapies in the United States 13.7 EU4 and the UK Market Size 13.7.1 Total Market Size of HER2+ Gastric Cancer (including GEJ) in EU4 and the UK 13.7.2 Market Size of HER2+ Gastric Cancer (including GEJ) by Current and Emerging Therapies in EU4 and the UK 13.8 Japan Market Size 13.8.1 Total Market Size of HER2+ Gastric Cancer (including GEJ) in Japan 13.8.2 Market Size of HER2+ Gastric Cancer (including GEJ) by Current and Emerging Therapies in Japan 14 Unmet Needs 15 SWOT Analysis 16 KOL Views 17 Market Access and Reimbursement 17.1 United States 17.1.1 Centre for Medicare and Medicaid Services (CMS) 17.2 EU4 and the UK 17.2.1 Germany 17.2.2 France 17.2.3 Italy 17.2.4 Spain 17.2.5 United Kingdom 17.3 Japan 17.3.1 MHLW 17.4 Market Access and Reimbursement of HER2+ Gastric Cancer (including GEJ) 18 Appendix 18.1 Bibliography 18.2 Report Methodology 19 DelveInsight Capabilities 20 Disclaimer Related Reports HER2+ Gastric Cancer Pipeline HER2+ Gastric Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key HER2+ gastric cancer companies, including Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo, AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc., Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc., Bavarian Nordic, among others. HER2+ Gastric Cancer Epidemiology HER2+ Gastric Cancer Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the HER2+ gastric cancer epidemiology trends. Gastric Cancer Market Gastric Cancer Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key gastric cancer companies, including Hanmi Pharmaceuticals, Merck, Minneamrita Therapeutics, Taiho Pharmaceuticals, Bayer, among others. Gastric Cancer Pipeline Gastric Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key gastric cancer companies, including EMD Serono, Sumitomo Pharma, LintonPharm Co., Ltd., Rapa Therapeutics LLC, Jiangsu HengRui Medicine Co., Ltd., Janssen Pharmaceutical K.K., Genentech, Exelixis, Bristol-Myers Squibb, Pieris Pharmaceuticals, Inc., Pfizer, Leap Therapeutics, CSPC ZhongQi Pharmaceutical, Ellipses Pharma, Amgen, Hanmi Pharmaceutical, Taiho Oncology, Inc., Shanghai Henlius Biotech, LianBio LLC, Chengdu Kanghong Biotech,Eisai Inc., AB Science, Maxinovel Pharmaceuticals, Shanghai Miracogen Inc., GlaxoSmithKline, Hoffmann-La Roche, Merck Sharp & Dohme, Hutchison Medipharma Limited, Genome & Company, Minneamrita Therapeutics LLC, Suzhou Suncadia Biopharmaceuticals Co., Ltd., MacroGenics, ALX Oncology Inc., Codiak BioSciences, Turning Point Therapeutics, Inc., TCRx Therapeutics, InxMed (Shanghai) Co., Ltd., Imugene Limited, SOTIO Biotech, CARsgen Therapeutics Co., Ltd., Zymeworks Inc., NextCure, Inc., Phanes Therapeutics, Pieris Pharmaceuticals, Inc., Athenex, Inc., Curis, Inc., Qurient Co., Ltd., Acepodia Biotech, Inc., Sichuan Baili Pharmaceutical Co., Ltd., Tarus Therapeutics, Inc., Lumicell, Inc., Legend Biotech,Cue Biopharma, TORL Biotherapeutics, LLC, OBI Pharma, Inc, Astellas Pharma, HiberCell, Inc., Celon Pharma SA, Linnaeus Therapeutics, Inc., Inspirna, Inc., Klus Pharma Inc., Genzada Pharmaceuticals, Shanghai PerHum Therapeutics, VM Oncology, LLC, Immunomic Therapeutics, Peptron, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact Us Shruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP
